GP2 Immunotherapy Prompts Total DFS Response for Patients with HER2 3+ Breast Cancer


The GP2/GM-CSF combination demonstrated a 100% disease-free survival at 5 years for patients with HER2/neu 3–positive disease who received adjuvant trastuzumab.

Research presented at the 2020 San Antonio Breast Cancer Symposium found that the combination of GP2 immunotherapy and granulocyte-macrophage colony-stimulating factor (GM-CSF) prompted a 100% disease-free survival (DFS) rate for patients with HER2/neu 3–positive disease who received adjuvant trastuzumab (Herceptin).1

The final 5-year efficacy analysis of a phase 2b trial showed that the Kaplan-Meier–estimated 5-year DFS rate in patients with HER2/neu 3+ disease who were treated with GP2 plus GM-CSF and completed the Primary Immunization Series (PIS) was 100% compared with 89.4% (95% CI, 76.2%-95.5%) in patients who received placebo and GM-CSF (n = 50; P = .0338).

A pivotal phase 3 trial is being initiated to treat patients with HER2/neu 3+ in the neoadjuvant setting.

“The poster presented at the SABCS is important because the Kaplan Meier survival curves and demographic data further validate our promising HER2 3+ phase 2b data and support our plan to commence a phase 2 trial in 2021,” said Snehal Patel, CEO of Greenwich Life Sciences, Inc, in a press release.2

In the prospective, placebo-controlled, single-blinded, multicenter phase 2b basket trial (NCT00524277), investigators randomized patients with node-positive and high-risk node-negative breast cancer with tumors expressing any degree of HER2 expression (immunohistochemistry [IHC] 1-3+) to receive GP2/GM-CSF versus GM-CSF alone. The intent-to-treat (ITT) population was comprised of 180 patients; 168 patients were treated across 16 clinical sites, 96 of whom had HER2 3+ disease.

All patients enrolled received 6 intradermal injections of GP2 plus GM-CSF (500 mcg GP2; 125 mcg GM-CSF) or placebo plus GM-CSF alone at 125 mcg every 3 to 4 weeks as part of the PIS for the first 6 months. Four GP2+GM-CSF booster or placebo intradermal injections were administered every 6 months thereafter. Boosters were introduced during the study, thus there were some patients who did not receive all 4 boosters.

Ninety-six patients with HER2 3+ disease received standard adjuvant trastuzumab and subsequently completed the complete PIS or placebo; the PIS was started a median 17.1 months following surgery. Seventy-two patients with HER2 1 to 2+ disease, who did not receive trastuzumab following surgery and then completed the full PIS or placebo, started the PIS at a median of 10.8 months following surgery.

The primary end point of the trial was recurrence rates; secondary end points were correlation with immune response and clinical outcomes, and unexpected toxicities.

The investigators noted that since GP2 is synergistic with trastuzumab, and the patients with HER2 1 to 2 + disease were not treated with trastuzumab, the study design was prespecified to compare recurrence rates with ITT versus per protocol in these 2 distinct, independently reported populations, excluding those who did not complete the PIS.

Results also showed that the estimated 5-year DFS rate in those with HER2 1-2+ disease who received the combination and completed the PIS (n = 35) was 77.1% (95% CI, 59.5%-87.9%) vs 77.6% (95% CI, 60.1%-88.2%) in those who received placebo/GM-CSF (n = 37; P = .9142).

Regarding safety, GP2 was also found to be well tolerated with no serious adverse effects reported.

"Recurring breast cancer affects 1 in 8 women. Approximately 50% of women with recurring breast cancer do not respond to [trastuzumab] or [ado-trastuzumab emtansine], resulting in metastatic breast cancer and a poor prognosis,” Patel concluded. “Approximately 80-85% of [patients with] metastatic breast cancer do not survive. By addressing this unmet need, GP2 may reach a potential market exceeding $5 billion.”


1. Patel SS, Williams DB, Patel MS, et al. Five year median follow-up data from a prospective, randomized, placebo-controlled, single-blinded, multicenter, Phase IIb study evaluating the reduction of recurrences using HER2/neu peptide GP2+GM-CSF vs. GM-CSF alone after adjuvant trastuzumab in HER2 positive women with operable breast cancer. Presented at: 2020 San Antonio Breast Cancer Symposium; December 8-11, 2020; virtual. Abstract PS10-23.

2. Greenwich LifeSciences announces poster presentation of five year data for GP2 phase IIb clinical trial, showing 0% recurrence of breast cancer. News release. Greenwich LifeSciences. December 9, 2020. Accessed December 10, 2020.

Related Videos
Exercise and healthy lifestyles can lower the risk of cancer or the symptoms of cancer treatment despite having genetic dispositions, said Neil M. Iyengar, MD.
Future analyses will look at durvalumab/olaparib for endometrial cancer populations with TP53 and POLE alterations, as well as those with estrogen receptor and progesterone receptor positivity.
Patients with mismatch repair proficient, newly diagnosed, advanced or recurrent endometrial cancer may have enhanced benefit with the addition of olaparib to durvalumab.
The Hispanic Breast Cancer Clinic at Northwestern Memorial Hospital includes a social worker, nurse practitioners, a medical oncologist, a radiation oncologist, and surgeons, says Claudia Tellez, MD.
The goal of creating the Hispanic Breast Cancer Clinic at Northwestern Memorial Hospital is to establish a safe space for Hispanic patients, says Claudia Tellez, MD.
Several factors may contribute to the low Hispanic breast cancer population at Northwestern Memorial Hospital, including a lack of resources and a focus on other disease types.
Sara M. Tolaney, MD, MPH, an expert on breast cancer
Sara M. Tolaney, MD, MPH, an expert on breast cancer
Related Content